Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

Stock Information for Genelux Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Genelux Corporation

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.